Lian Yong Chen

China Life Sciences Access Fund LP is a venture capital fund that operates in the life sciences industry. The private company is based in George Town, Cayman Islands.

Neusoft Medical Systems Co., Ltd. engages in the research, development, manufacturing, and sale of large-scale medical diagnosis and treatment equipment and solutions as well as the provision of related services. Its products include computed tomography systems, magnetic resonance imaging systems, digital subtraction angiography systems, ultrasonic diagnostic equipment, positron emission tomography equipment, radiotherapy products, as well as in vitro diagnostic equipment and reagents. The company was founded on March 6, 1998 and is headquartered in Shenyang, China.

6 Dimensions Capital is an independent private equity firm headquartered in China. The firm was founded in 2017.

Fog Pharmaceuticals, Inc. develops pharmaceutical products. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane and is headquartered in Cambridge, MA.

TenNor Therapeutics Suzhou Ltd. manufactures pharmaceutical products. It specializes in research and development of new drugs for the treatment of digestive diseases caused by pathogens, including those resistant to available antibiotics. The company was founded by Zhen Kun Ma in 2013 and is headquartered in Suzhou, China.

Engine Biosciences Pte Ltd. develops novel combinations of genes and drugs for therapeutic and industrial purposes. The company was founded by Timothy Lu and Jeffrey Lu and is headquartered in Singapore.

Tengsheng Boyao Pharmaceutical Technology Shanghai Co., Ltd. engages in research and development of medical technology. The company was founded by Zhi Hong on April 19, 2018 and is headquartered in Shanghai, China.

Tongrun Biomedicine (Shanghai) Co., Ltd. develops tumor immunotherapy drugs. The company is based in Shanghai, China.

Hua Medicine (Shanghai) Co., Ltd. is a Chinese biotechnology company that focuses on the clinical needs of diabetic patients. The private company is based in Shanghai, China. The company has brought together high-end talents and scientific and technological resources to develop the world's first dorzagliatin (hms5552) for the treatment of type 2 diabetes. Hua Medicine has conducted two phase III clinical trials in 2019, targeting type 2 diabetes patients who have failed to treat the disease with other medications. The company plans to expand the advanced concepts of personalized therapy and management of diabetes to achieve effective control of diabetes and metabolic diseases and complications. The company was founded in 2011 by Li Chen, who has been the CEO since then.

Part of Cutia Therapeutics, Cutia Therapeutics (Shanghai) Co., Ltd. develops therapeutics to treat severe facial acne vulgaris. The private company is based in Shanghai, China. The Chinese company was founded in 2019. The CEO is Le Le Zhang.